Advertisement


Related Videos

Deborah Collyar: What's In It for Patients?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement



Nov
28
Today In Oncology
Presence of Tumor-Infiltrating Lymphocytes Following Neoadjuvant Treatment May Contribute to Worse Survival in Patients With HER2-Positive Breast Cancer
Intraoperative Ultrasound vs Wire Localization in Surgery for Ductal Carcinoma in Situ
Effect of Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Patients Aged 70 and Older Receiving Treatment for Advanced Cancer
5-Year Outcomes With Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma
5-Year Survival and Cure Fraction Estimates for Childhood Cancer in Europe From 2000 to 2014 EUROCARE-6
View More 
Advertisement
© 2022 HSP News Service, L.L.C.
Designed by Harborside